Bizaxofusp
- Generic Name
- Bizaxofusp
- Drug Type
- Biotech
- CAS Number
- 1236019-35-4
- Unique Ingredient Identifier
- FRY3MOL2QU
Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma
Phase 2
Completed
- Conditions
- GlioblastomaGlioblastoma MultiformeGrade IV GliomaGrade IV Astrocytoma
- Interventions
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2022-10-24
- Lead Sponsor
- Medicenna Therapeutics, Inc.
- Target Recruit Count
- 47
- Registration Number
- NCT02858895
- Locations
- 🇺🇸
John Wayne Cancer Institute at Providence Saint John's Health Center, Santa Monica, California, United States
🇺🇸Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
Convection Enhanced Localized Administration of PRX321 With Real-time Imaging for Therapy of Recurrent Glioblastoma (CLARITY-1)
- First Posted Date
- 2008-11-25
- Last Posted Date
- 2012-12-03
- Lead Sponsor
- Sophiris Bio Corp
- Registration Number
- NCT00797940
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath